Flash deal
Buy 1 get 1 free
Ends in
0Days00Hours00Mins
Time left38%

Ipamorelin 5mg Peptide

In stock

Lab tested · Mar 2023
£19.95
Buy 1 get 1 free Mix and match. The cheaper one is free.
Until Thu 19 Nov, 19:00 or while the amount lasts. Pairs aren't part of 3 for 2.

Buy 1 get 1 free

Decline Buy 1 get 1 free deal

Supplied for Research Purposes Only. This product and the information provided are intended solely for laboratory research. We do not provide guidance on human use. These products are for sale to persons aged 18 and over only. Customers are responsible for checking the legal status of the product in their own jurisdiction before purchase.

Ipamorelin 5mg is supplied as a research vial of a synthetic pentapeptide. Its selective growth hormone-releasing profile and activity at the ghrelin receptor have attracted research into both endocrine signalling and gastrointestinal motility.

Check out our Independent Lab Analysis (opens in a new window).

For information on reconstituting peptides, see our guide: How to Reconstitute Peptides with Bacteriostatic Water: A Step-by-Step Guide .

Certificate of analysis

Independently tested by MZ Biolabs

All lab reports
View full certificate from 1 March 2023 (PDF, opens in a new tab)

Latest result

Most recent test
  • 99.5% Purity
  • 4.98 mg Calculated amount 99.5% purity of 5 mg
Sample tested
Not stated
Analysis date
1 March 2023
Laboratory
MZ Biolabs
Lab lot
2023-02-27
Identity
Molecular weight confirmed
Method
Mass Spectrometry and UV

Testing history

  1. 1 March 2023 Purity 99.5% PDF
  2. 16 June 2021 Purity 99.2% PDF

Ipamorelin: selective secretagogue research

Ipamorelin 5mg is a five-amino-acid peptide developed under the research code NNC 26-0161. It is studied as a ghrelin-receptor agonist, with particular interest in its growth hormone-releasing profile and its differences from other peptide secretagogues.

Why selectivity matters

The original pharmacology programme compared ipamorelin's GH response with other pituitary and adrenal hormone responses. Its relative selectivity in those experiments gave researchers a useful tool for investigating GH release without assuming that all secretagogues share the same endocrine profile. Selectivity describes the conditions studied and should not be read as a guarantee of freedom from adverse effects.

Beyond the pituitary: gastrointestinal motility

Ghrelin signalling also participates in gut movement. Animal studies explored ipamorelin's effects on gastrointestinal transit after surgery, leading to a randomised phase 2 trial in bowel-resection patients. That trial measured recovery of tolerance to solid food, illustrating a distinct clinical research direction beyond the GH axis.

The human trial did not show a statistically significant advantage over placebo in its key or secondary efficacy analyses. It nevertheless helps define which translational questions remain open: promising receptor pharmacology and animal findings need confirmation for each proposed clinical outcome.

Also known as / branded as

  • NNC 26-0161
  • NNC-26-0161

Products are supplied for research purposes only and are for sale to persons aged 18 and over.